PPT-The Problem of Substandard Medicines in Developing Countries

By Laura Christian Linda Collins Maythiwan Kiatgrajai Agathe Merle Nayantara Mukherji Alissa Quade Outline Methodology Overview Definitions Harmful Effects Extent of the Problem. M ONITORING M EDICINES (FP7 G RANT N O 223566) D8 - MEDICINES OVERSEE A PILOT PROJECT AIMED AT DEVELOPMENT OF TOOLS TO IDENTIFY REPORTS INDICATING SUBSTANDARD MEDICINES G HAZALEH K HODABAKHSHI K Global context of drug regulation. Dr Lembit Rägo. Coordinator. Quality Assurance and Safety: Medicines. Essential Medicines and Health Products. World Health Organization. E-mail: . ragol@who.int. Thalidomide was found to be unsafe for pregnant women as it affected their developing foetuses. Many women who took the drug gave birth to babies with severe limb deformities. . Later on Doctors discovered thalidomide could cure leprosy and started for patient suffering with the disease in the developing world. But again children were born with abnormalities.. Developed:. Higher income. Industrial economies. Slow population growth. Stronger social support systems. Ex: US, Canada, Japan, Australia & countries of western Europe. B. . Developing:. 1.Lower income. Gender and health in developing countries . Gender and health in developing countries . Gender and health in developing countries . Gender and health in developing countries . Gender and health in developing countries . Francisci. WG.8. Developed vs. Developing Countries. Indicators of Economic Development. Developed Countries. Developing Countries. 1. Availability. of natural resources (Examples: water, . oil. Greg Perry. Melbourne – International AIDS Conference. July 2014. 1. The Future of HIV Treatment?. All people on treatment have access to the best possible regimens. Treatment side effects are minimal or non-existent. Esteban Burrone, . July 2017. THE MEDICINES PATENT POOL: A PUBLIC HEALTH VOLUNTARY LICENSING ORGANIZATION. Founded in 2010 by. To increase . access. to new treatments for HIV. And facilitate . innovation . By Laura Christian, Linda Collins, . Maythiwan. . Kiatgrajai. , . Agathe. Merle, . Nayantara. . Mukherji. , Alissa . Quade. Outline. Methodology. Overview. Definitions. Harmful Effects. Extent of the Problem. Khartoum, 6-8 December 2014. Dr Lembit Rägo. Head, Regulation of Medicines and other Health Technologies . Essential Medicines and Health Products. WHO Member State Mechanism. Member State Mechanism – Work Plan. G. eneric . M. edicines and Formulations. Esteban Burrone and . Aastha. Gupta. Medicines Patent Pool. July . 2018. Over 90% . of the HIV medicines procured in LMICs are made by generic manufacturers*, many of whom are present here today. Khartoum, 6-8 December 2014. Dr Lembit Rägo. Head, Regulation of Medicines and other Health Technologies . Essential Medicines and Health Products. WHO Member State Mechanism. Member State Mechanism – Work Plan. USP Global Public Policy PositionCombatting Substandard and Falsi31ied Medicines2ISSUE Substandard and falsi31ied medicines pose a major threat to global health Poor-quality medicines cause more than TRADING AWAY HEALTH: THE TRANS-PACIFIC PARTNERSHIP AGREEMENT (TPP) MSF Access Campaign Médecins Sans Frontières, Rue de Lausanne 78, CP 116, CH-1211 Geneva 21, Switzerland Tel: + 41 (0) 22 849 84